COMPUMEDICS LIMITED — Regulatory Filings 2021

Aug 9, 2021

==> picture [364 x 85] intentionally omitted <==

Cover sheet to be added – Simone Corporate Presentation October 2019

==> picture [128 x 25] intentionally omitted <==

1

Who is Compumedics?

A leading global, innovative developer and manufacturer of medical devices for:

==> picture [87 x 296] intentionally omitted <==

Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including longHighly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain research brain (Transcranial (LTEM) Doppler [TCD]) A technological leader in its chosen markets: #1 China sleep #3 USA sleep diagnostic #1 Australian sleep & #1Japan sleep diagnostic device device supplier and neuro diagnostics device diagnostics device supplier to premier emerging #3 supplier for supplier supplier facilities & #1 TCD neurological monitoring device supplier devices FY21 – results to be released August 24 approximately – update provided to ASX on 19[th] July 2021 FY22 Guidance to be reviewed with release of FY21 results. 130 employees across seven locations, Melbourne, Australia (Head Office), Charlotte, NC, USA, Hamburg, Dresden and Singen, Germany, Paris, France and Daejeon, South Korea. Compumedics listed ASX Dec 21, 2000. CMP has market capital of around $80m.

==> picture [90 x 296] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

All $ = A$ unless otherwise specified

2

6 reasons to buy Compumedics

• 1 Proven and established MedTech leader in its chosen markets with strong balance sheet and sound growth strategy

2 Core markets in sleep and neuro diagnostics / monitoring offer solid growth platform

3 Multiple upside “New Generation” incremental step-out opportunities imminent

• 4 Core business - Multiple new product and service platforms to launch commercially

5 Existing track record to enable step out into digital / eHealth areas 6 Established and proven geographical and product diversification

==> picture [128 x 25] intentionally omitted <==

3

Core Business – Premium Focus

	Sleep Diagnostics	Neuro Diagnostics – Clinic	Neuro Diagnostics - Research	Brain Blood Flow Diagnostics
Global market – USD pa	250m	1,300m	20m	15m
Compumedics
market share	6%	<1%	30%	35%
(approximate)
Compumedics market position	Aust – 1 USA – 3 China - 1	Aust – 1 USA – 3 China - 1	Aust – 1 USA – 1 China – 1	Aust – 1 USA – 2 China – 1 Germany – 1
Business and	Capital equip –	Capital equip –	Capital equip –	Capital equip –
product type	hardware and software	hardware and software	hardware and software	hardware and software
Annuity revenues –
~ % of total –	15%	10%	5%	5%
supplies & support

==> picture [128 x 25] intentionally omitted <==

4

Diversified Product Portfolio

==> picture [702 x 364] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

5

Revenue Composition at $18.0m for H1 FY21 31 December 2020 – half year

By geographic region

By product/market

==> picture [576 x 231] intentionally omitted <==

----- Start of picture text -----

Customer Care 9%
Consumables 11%
Europe, USA,
Sleep -
30% 29% Clinical
Brain -
Diagnostics
Blood Flow
23%
Monitoring
24% Sleep -
Nexus360
Aust, 2%
Brain -
Asia, 14% Research Brain - Clinical
27% 14% Monitoring 18%
----- End of picture text -----

Software upgrades 5 to 10% of system revenues. MEG included in Brain – Research

Compumedics sells directly to end-user customers in Australia, USA, France and Germany and through its network of more than 50 distributors to all other parts of the world

==> picture [128 x 25] intentionally omitted <==

6

Pandemic resilient

==> picture [702 x 388] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

7

Growth Platform – Core and Step-Out

==> picture [669 x 168] intentionally omitted <==

----- Start of picture text -----

Sales – schematic only
----- End of picture text -----

==> picture [559 x 31] intentionally omitted <==

----- Start of picture text -----

FY19A FY20A FY21F FY22F FY23F
Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit)
----- End of picture text -----

• Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Institute in Phoenix, AZ, USA has been undertaken and the second and final phase, which was COVID-19 delayed, is currently planned for early 2021. It confirms that we can transition from a USD30k software sale to a USD3.5m complete system sale. Additional sales opportunities being actively pursued.

• Step-out - SLEEP - CLOUD GROWTH – Nexus 360 cloud-based professional sleep diagnostic solution sold to more than 46 sites in US and Australia and generated revenues of about $1m in FY20. Annual contracted fees now over $1.5m. Somfit development and discussions continue, including as a multi-modal COVID-19 monitor.

• Core - SLEEP & NEURO – DIAGNOSTIC GROWTH – Mid-market devices selling and with a complete range of new ambulatory devices for 2021. Neurology remains a key focus for core business growth in Asia, China, US and other key markets.

*MEG = Magnetoencephalography

==> picture [128 x 25] intentionally omitted <==

8

Next Generation Growth – Core and Step-out

	Sleep Diagnostics	Neuro Diagnostics – Clinic	Neuro Diagnostics - Imaging	Brain Blood Flow Diagnostics
Next generation growth platform	Cloud based sleep diagnostic platforms for both professional and consumer applications	Long term epilepsy market penetration into US, Europe and Asia	Leverage CURRY software into full MEG solution with KRISS	Leverage existing TCD technology and patent to Traumatic Brain Injury (TBI) application
Market potential	Professional application > USD3bn pa Consumer application > USD50bn pa	Greater than USD100m pa	Research only USD100m pa Brain Imaging >USD4bn pa	Estimated cost of TBI’s in the US alone greater than USD76bn pa
Business type	Services – fee per service	Capital equipment – bigger market	Capital equipment & Partnership – new market	Mixture of equipment and service fees

==> picture [128 x 25] intentionally omitted <==

9

Core Business - Growth Drivers

==> picture [43 x 82] intentionally omitted <==

Compumedics/Neuroscan innovative brain analysis software and high-performance amplifiers are unrivalled world class technology. Curry 9 releasing FY21

We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics.

Earnings initiatives to continue to flow through in FY21 – FY22. New range of ambulatory products for sleep and neurology releasing FY21.

USA business growing with further modifications and enhancements to the team being implemented to support stronger growth across the entire business there.

==> picture [35 x 40] intentionally omitted <==

Continued expansion into untapped German market and ongoing growth in France.

==> picture [53 x 33] intentionally omitted <==

Continuing growth in China for sleep diagnostics, with a stronger emphasis on the neuro diagnostic and monitoring market there.

Ideally positioned to accelerate organic growth and value realisation

==> picture [128 x 25] intentionally omitted <==

10

New products launching in late 2021, early 2022

==> picture [230 x 192] intentionally omitted <==

==> picture [246 x 189] intentionally omitted <==

==> picture [235 x 167] intentionally omitted <==

==> picture [205 x 167] intentionally omitted <==

==> picture [251 x 108] intentionally omitted <==

==> picture [439 x 142] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

11

The basis for our movement to digital / eHealth

==> picture [702 x 394] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

12

Step out 1 - Brain Imaging:

Opportunity

Market & Competition

Outcome

Plan

CMP’s CURRY brain analysis software is already the gold standard for the MEG market MRI* is too slow to capture dynamic brain activity needed for alzheimer's et al

The MEG market is currently estimated at about 20 systems a year at an average selling price of USD4.0m each = US$80m/annum

Calendar 2021 – second CMP has sold and and final phase of MEG partially installed 1 installation planned to MEG system in be undertaken at BNI FY19 FY21/early FY22 – CMP has achieved Secure second MEG FDA for Orion MEG sales

This is expected to grow about 10% a year, excluding China

CMP has achieved FDA for Orion MEG

CMP’s agreement with KRISS provides access to a new and superior hardware platform

CMP expects to sell a further 1 MEG systems in early FY22

The dominant existing player is Megian (previously Elekta). CTF MEG (is a much smaller player)

Compumedics can access a complete MEG sale (circa USD3 to 4m each) as opposed to the USD30k software sale

==> picture [369 x 158] intentionally omitted <==

CMP expects to double sales in FY22/23 to 2 to 4 MEG systems

• MEG = Magnetoencephalography *MRI = Magnetic resonance imaging

==> picture [128 x 25] intentionally omitted <==

13

Step out 2 - eHealth – Cloud Sleep Diagnostics

Nexus 360 (professional cloud sleep diagnostics) sold into more than 46 US and Aust. sites with over 270 beds and generated revenues of $1m in FY21 Contracted

revenues now running at $1.5m pa run rate as we exited FY20.

Operational systems have been developed for the cloud-based capture, transfer

Compumedics is Key partners continuing to seek being pursued appropriate third include web, parties to expedite the telco, eHealth, process and take the consumer Somfit consumer device health/ to targeted market electronics opportunities. providers and device manufacturers.

and translation of medical grade sleep parameters from any webenabled device. The system can then store, analyse and interpret that data in a simple and actionable manner, reducing the need for on-site professionals.

==> picture [486 x 169] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

14

Directors & Executive Team Key Management

==> picture [124 x 94] intentionally omitted <==

==> picture [134 x 104] intentionally omitted <==

==> picture [105 x 108] intentionally omitted <==

David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs

Mr. David Lawson Chief Financial Officer & Company Secretary CMP Tenure 20 yrs

Mr Tucson Dunn Non Executive Director CMP Tenure 12 months

==> picture [111 x 74] intentionally omitted <==

Mr. Warwick Freeman Chief Technology Officer CMP Tenure 26 yrs

==> picture [79 x 69] intentionally omitted <==

Kerry Hubick, Ph.D. Trademark, Patent & General Legal Attorney CMP Tenure 11 yrs

==> picture [101 x 74] intentionally omitted <==

Mr. Christoph Witte General Managing Director Compumedics Germany GmbH CMP/DWL - Tenure 29 yrs

==> picture [43 x 46] intentionally omitted <==

==> picture [44 x 40] intentionally omitted <==

==> picture [39 x 40] intentionally omitted <==

==> picture [38 x 40] intentionally omitted <==

==> picture [43 x 42] intentionally omitted <==

==> picture [70 x 38] intentionally omitted <==

==> picture [29 x 47] intentionally omitted <==

==> picture [29 x 21] intentionally omitted <==

==> picture [38 x 34] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

15

Investor Summary

Core business profitable with on-going growth opportunities in key global markets

Compumedics remains committed to continuing to deliver superior returns to shareholders Spin off/strategic decisions to unlock significant value, provide funds for growth and potentially capital returns to shareholders

==> picture [287 x 283] intentionally omitted <==

International sales force

expansion , neurology and sleep market opportunity and earnings improvement initiatives to continue to drive growth of core business

Brain imaging and e-Health are the next steps Moving 25+years and $100m+

in cumulative R&D to a modern platform to solve massive and growing problems of neuro imaging in clinic and sleep disorders in the home

FY22 guidance: Guidance to be reviewed on release of FY21 results

==> picture [128 x 25] intentionally omitted <==

16

==> picture [205 x 48] intentionally omitted <==

Disclaimer

This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statement. These forward-looking statement have been made based upon CMP’s expectations and beliefs concerning future developments and their potential effect on CMP (and it’s controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP’s control. No assurance is given that future developments will be in accordance with CMP’s expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.

Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.

==> picture [128 x 25] intentionally omitted <==

compumedics.com.au

17

==> picture [205 x 48] intentionally omitted <==

==> picture [128 x 25] intentionally omitted <==

compumedics.com.au

18